Blog

In January 2021, Pfizer, the manufacturer of the rheumatoid arthritis drug Xeljanz®, announced the results of the safety clinical trial mandated by the U.S. Food and Drug Administration (FDA). The study analyzed the safety of tofacitinib, the active ingredient in Xeljanz, at two doses: 5 mg twice daily and 10 mg twice daily. Patients taking Xeljanz at…

Popular rheumatoid arthritis, psoriatic arthritis, and ulcerative medication Xeljanz has been potentially linked to MACE injuries, strokes, and blood clots through a clinical study. These injuries require extensive treatment. For additional information on the Xeljanz lawsuits, see our Xeljanz Area of Practice page. Treatment for MACE Injuries Major Adverse Cardiac Events (MACE) injuries include: Heart…

Popular rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis medication Xeljanz has been potentially linked to causing strokes and blood clots. Review our Xeljanz Safety Evaluation Timeline for more information on the approval history of Xeljanz and the study potentially connecting Xeljanz to strokes and blood clots. Xeljanz is also linked to Major Adverse Cardiac Events (MACE)…

Xeljanz and MACE Injuries Preliminary results from an FDA-mandated study conducted by Xeljanz and Xeljanz XR’s manufacturer, Pfizer, found that patients taking the popular rheumatoid arthritis medication are at an increased risk of developing serious heart-related injuries.  Xeljanz is also used to treat psoriatic arthritis and ulcerative colitis. The preliminary results of the study were concerning…